



BETA DRUGS LIMITED

2nd CORRIGENDUM TO THE NOTICE OF THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON TUESDAY, NOVEMBER 12, 2024 AT 10.30 A.M.

An Extraordinary General Meeting (“EGM”) of the Members of BETA DRUGS LIMITED (“the Company”) is scheduled to be held on Tuesday, **November 12, 2024 AT 10:30 A.M.**

The Notice of the EGM (“EGM Notice”) was dispatched to the Shareholders of the Company on **19TH October, 2024** in due compliance with the provisions of the Companies Act, 2013, and rules made thereunder, read with circulars issued by Ministry of Corporate Affairs and Securities Exchange Board of India and all other applicable provisions.

The Company had filed applications with the stock exchange namely NSE Limited (“NSE”), for seeking in-principle approval in relation to the proposed preferential issue of Equity Shares & Compulsory Convertible Debentures for which the approval of the shareholders is being sought. Thereafter, the Company has received observations from NSE through e-mail dated 25th October, 2024 and has directed the Company to rectify / provide additional details through Corrigendum and Company has issued Corrigendum on 28th October, 2024. Thereafter, the Company has received 2nd observations from NSE through e-mail dated 4th November, 2024 and has directed the Company to rectify / provide additional details through Corrigendum. This 2nd Corrigendum is being issued to notify the amendments/ provide clarifications & additional details with respect to certain disclosures made under the explanatory statement to Item No. 2, which is annexed to the Notice (“Explanatory Statement”), as mentioned herein:

1 In the explanatory statement “Item No. 2”, point 1 should be read as follows:

1. Object of the preferential issue of equity shares:

Subject to applicable law, the Company shall utilize the proceeds from the preferential issue for funding capital investment or expenditure requirements of the Company and its subsidiaries (including, by way of investment in its subsidiaries) and other general corporate purposes. The Company will use the Subscription Amount for the following purposes:

Sr. No	Use of Funds	Estimated Amount (Rs. in cr)	Timeline
1	Facility Upgradation of 100% Subsidiary - Adley Formulations P Ltd.	8	within 24 months from the date of allotment of CCD's
2	Facility Upgradation of 100% Subsidiary - Adley Lab Ltd.	5	
3	R & D facility (new setup)	15	
4	Geographical Expansion	10	
	4.1 New Registrations		
	4.2 Audits		
	4.3 Dossiers costs		
	4.4 Bioequivalence studies costs		
5	Capital Expenditure (Manufacturing- new setup)	44	
6	Capital Investment (including capital acquisitions)	20	
7	General Corporate	15	
	Total	117	

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com

The fund requirement and the proposed utilization schedule are based on management estimates, market conditions, business needs and other commercial and technical factors, and the actual deployment of funds at each stage will depend on a number of factors such as financial, market and sectoral conditions, business performance and strategy, and other external factors (such as competitive environment, pandemic and related government requirements, employment and disposable income levels, demographic trends, technological changes, changing customer preferences and increasing regulations or changes in government policies), which may not be within the control of the Company and may result in modifications to the proposed schedule for utilization of the net proceeds at the discretion of the Board, subject to compliance with applicable laws.

Pending utilization of the proceeds from the Preferential Issue, the Company may invest such proceeds in money/debt market instruments (including mutual funds and liquid funds), deposits in scheduled commercial banks, or any other avenues as permitted under applicable laws.

Further it is confirmed that company will not invest in capital eroding and high risk taking instruments and all other investment shall be done in compliance with the applicable laws.

2. In the explanatory statement "Item No. 2", point 8 should be read as follows:

8. Identity the Proposed Allottee and the percentage of post preferential issue capital that may be held by them:

To meet the object of the issue, below Proposed Allottee, has shown its intent to subscribe to Equity Shares and CCDs of the Company.

Name of the Proposed Allottees	Category	Pre issue Shareholding		No. of equity shares to be allotted	No. of CCD shares to be allotted	Post issue Shareholding		Post issue Category
		Number	% of shares			Number	% of shares	
Healthquad Fund II (a scheme under Healthquad Trust II)	Non-promoter	0	0.00%	70	4,53,623	4,53,693	4.40%	Non-promoter
Inti Capital VCC - Inti Capital I	Non-promoter	0	0.00%	30	2,11,691	2,11,721	2.05%	Non-promoter
Generational Capital Breakout Fund 1	Non-promoter	14,000	0.15%	0	42,337	56,337	0.55%	Non-promoter

This 2nd corrigendum to the EGM Notice shall form an integral part of the EGM Notice and Corrigendum, which has already been circulated to the Shareholders of the Company and on and from the date hereof, the EGM Notice shall always be read in conjunction with this Corrigendum. This 2nd Corrigendum will be made available on website of the stock exchange i.e. NSE and on the website of the Company.

All other contents of the EGM Notice, save and except as modified or supplemented by this Corrigendum, shall remain unchanged.

By Order of the Directors

Place: Baddi
Date: 07.11.2024

sd/-
Ms. Rajni Brar
Company Secretary